Novabay Pharmaceuticals IncのEBIT margin
Novabay Pharmaceuticals IncのEBIT marginは何ですか。
Novabay Pharmaceuticals IncのEBIT marginは-88.70%です。
EBIT marginの定義は何ですか。
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
NYSEMKTのセクタHealth CareにおけるEBIT marginの企業と比べるNovabay Pharmaceuticals Inc
Novabay Pharmaceuticals Incは何をしますか。
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Incと類似のebit margin
- American ResourcesのEBIT marginは-90.91%です。
- Conversion LabsのEBIT marginは-90.27%です。
- Values Cultural Invest LtdのEBIT marginは-89.36%です。
- Lloyd Fonds AGのEBIT marginは-89.24%です。
- X2M ConnectのEBIT marginは-89.21%です。
- Valeo Pharma IncのEBIT marginは-89.04%です。
- Novabay Pharmaceuticals IncのEBIT marginは-88.70%です。
- Marin Software IncのEBIT marginは-88.54%です。
- Cuda Oil and GasのEBIT marginは-88.14%です。
- Nano MagicのEBIT marginは-87.45%です。
- StereotaxisのEBIT marginは-87.38%です。
- Vireo Health InternationalのEBIT marginは-86.53%です。
- Vivos TherapeuticsのEBIT marginは-85.90%です。